Month: November 2024

.Merck &amp Co. has actually grabbed alternatives on two Evaxion Biotech vaccination applicants, spending $3.2 thousand and also dangling much more than $1 billion in

.Merck &amp Co.’s long-running attempt to land a hit on small mobile lung cancer cells (SCLC) has racked up a little victory. The drugmaker’s Daiichi

.A period 3 test of Daiichi Sankyo and also Merck &amp Co.’s HER3-directed antibody-drug conjugate (ADC) has actually struck its primary endpoint, boosting strategies to

.Gilead Sciences as well as Merck &amp Co. have led their once-weekly HIV combination therapy past one more landmark, linking the cocktail to continual suppression

.MBX has expanded programs to consume over $136 thousand from its own IPO as the biotech seeks to carry a prospective opposition to Ascendis Pharma’s

.MBX Biosciences has actually contributed to the latest flurry of IPO filings. The biotech, which submitted its paperwork weeks after elevating $63.5 thousand confidentially, is

.Complying with a bad revealing for Lykos Therapies’ MDMA candidate for trauma at a latest FDA advisory board appointment, the various other footwear possesses dropped.On

.Psychopharmacology has actually drawn 3 posts concerning midstage professional trial records analyzing Lykos Therapies’ investigational MDMA applicant for managing post-traumatic stress disorder (PTSD). The journal

.Lykos Therapeutics might possess lost three-quarters of its staff following the FDA’s rejection of its own MDMA prospect for trauma, however the biotech’s brand-new leadership

.Lundbeck is reducing the book market value of its $250 thousand Abide Therapies purchase in reaction to stage 1 record that set off a very